Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

African heritage diets are increasingly being replaced by Western-style dietary patterns because of urbanization, economic development, increased access to processed foods, globalization and changing social norms. 2 key findings →

Design: randomized controlled trial Evidence: high

Cognitive training involving speed of cognitive processing has the potential to delay the diagnosis of ADRD. 1 key finding →

Design: randomized controlled trial Participants: 2,021 Evidence: high

Participants receiving CDCM showed significantly fewer behavioral and psychological symptoms (adjusted mean difference [AMD] in NPI score, -10.26 [95% CI, -16.95 to -3.58]; P = .003; Cohen d, -0.78 [95% CI, -1.09 to -0.46]), better mental health (AMD in SF-12 Mental Component Summary score, 2.26 [95% CI, 0.31-4.21]; P = .02; Cohen d, 0.26 [95% CI, -0.11 to 0.51]), and lower caregiver burden (AMD in BIZA-D score, -0.59 [95% CI, -0.81 to -0.37]; P Conclusions and relevance In this secondary analysis of a cluster randomized clinical trial, CDCM was associated with improved patient, caregiver, and health system-relevant outcomes over 36 months beyond the intervention period. 3 key findings →

Design: RCT Participants: 428 Evidence: high

The non-linear function indicates that a higher dose is not necessarily better in multidomain interventions. 3 key findings →

Design: randomized controlled trial Participants: 749 Evidence: high

In this study, quantitative results were inconclusive owing to small sample size. 5 key findings →

Design: randomized controlled trial Participants: 25 Evidence: high

Home based support for caregivers of persons with dementia, which emphasizes the use of locally available, low-cost human resources, is feasible, acceptable and leads to significant improvements in caregiver mental health and burden of caring. 3 key findings →

Design: randomized controlled trial Evidence: high

As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. 5 key findings →

Design: randomized controlled trial Evidence: high

Cognitive stimulation therapy (CST) is a well-established group psychosocial intervention for people with dementia. 4 key findings →

Design: randomized controlled trial Evidence: high

Digital Detection of Dementia in Primary Care: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA Network Open 2025-11-03

Compared with the usual care clinics (12-month incidence, 213 of 1724 [12.4%]), the odds of an incident ADRD diagnosis were higher in the clinics randomized to QDRS plus PDM (12-month incidence, 355 of 2301 [15.4%]; adjusted odds ratio [AOR], 1.31; 95% CI, 1.05-1.64) but not the clinics randomized to PDM only (12-month incidence, 134 of 1300 [10.3%]; AOR, 0.84; 95% CI, 0.63-1.11]). 3 key findings →

Design: RCT Participants: 5,325 Evidence: moderate

Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Alzheimer's research & therapy 2021-02-23

This is the first randomized trial to investigate the impact of a ketogenic diet in patients with uniform diagnoses of AD. 3 key findings →

Design: randomized controlled trial Participants: 26 Evidence: high

Scale of benefit is comparable with in-person training, indicating its potential as a public health intervention. 3 key findings →

Design: randomized controlled trial Participants: 2,912 Evidence: high

Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Clinical Infectious Diseases 2000-08-01

The of establishing the diagnosis of pneumonia and cause is with the antibiotic studies for of community-acquired studies for of community-acquired The diagnosis of is based on a of clinical and laboratory The diagnosis of is and and as well as disease, congestive heart failure, with pneumonia and cases of and are of do not require and are the of antibiotic antimicrobial is usually for and a chest radiography is usually to establish the diagnosis of examination to or is for detecting pneumonia Chest radiography is considered is for the etiologic the and or conditions. 5 key findings →

Design: randomized controlled trial Evidence: high

The MBI component significantly improved multiple caregiver outcomes, with reduced depressive symptoms (β = -2.13 [95% CI, -2.85 to -1.38]; P Conclusions and relevance In this clinical trial of informal caregivers of people with dementia, synergistic interaction effects were noted for MBI, which enhanced the benefits of SC and BPM on depression. 2 key findings →

Design: RCT Participants: 250 Evidence: moderate

Although antipsychotics were associated with greater harm than antidepressants and anticonvulsants in subgroups of persons with dementia, medications used in lieu of antipsychotics for treating neuropsychiatric symptoms in dementia, such as anticonvulsants and dextromethorphan-quinidine, were also associated with harm. 5 key findings →

Design: randomized controlled trial Participants: 209 Evidence: high

Overall, we showed that SDB was associated with MTL atrophy in cognitively asymptomatic older adults engaged in the Alzheimer continuum, which may increase the risk of developing memory impairment over time. 3 key findings →

Design: randomized controlled trial Participants: 122 Evidence: high

This cohort study of Medicare beneficiaries suggests that use of antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors was associated with lower risk of ADRD compared with antihypertensive medications that inhibit these receptors. 5 key findings →

Design: randomized controlled trial Participants: 57 Evidence: high

Ageing of the population, together with population growth, has brought along an ample increase in the number of older individuals living with dementia and disabilities. 5 key findings →

Design: randomized controlled trial Evidence: high

The plush toy used in this study offered marginally greater value for money than PARO in improving agitation. 4 key findings →

Design: randomized controlled trial Participants: 415 Evidence: high

Between April 30, 2020, and May 9, 2022, we randomly allocated 204 participants (109 [53%] women and 95 [47%] men) to the intervention group and 98 (60 [61%] women and 38 [39%] men) to the control group. 218 (72%) participants at 6 months and 178 (59%) at 12 months provided cost data. 2 key findings →

Design: RCT Participants: 302 Evidence: high

Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Archives of neurology 2011-06-01

Our results suggest that diet may be a powerful environmental factor that modulates Alzheimer disease risk through its effects on central nervous system concentrations of Aβ42, lipoproteins, oxidative stress, and insulin. 2 key findings →

Design: randomized controlled trial Participants: 29 Evidence: high

We were unable to detect a difference in HRQOL for screening for ADRD among older adults. 3 key findings →

Design: randomized controlled trial Participants: 2,008 Evidence: high

Baseline assessments were conducted on 128 participants. 3 key findings →

Design: randomized controlled trial Participants: 125 Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed